

Moosa Mohammadi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8346749/publications.pdf>

Version: 2024-02-01

141
papers

28,190
citations

8755

75
h-index

11052

137
g-index

179
all docs

179
docs citations

179
times ranked

23291
citing authors

#	ARTICLE	IF	CITATIONS
1	The FGF family: biology, pathophysiology and therapy. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 235-253.	46.4	1,548
2	Endocrine Regulation of the Fasting Response by PPAR α -Mediated Induction of Fibroblast Growth Factor 21. <i>Cell Metabolism</i> , 2007, 5, 415-425.	16.2	1,306
3	Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors. <i>Science</i> , 1997, 276, 955-960.	12.6	1,047
4	Crystal Structure of a Ternary FGF-FGFR-Heparin Complex Reveals a Dual Role for Heparin in FGFR Binding and Dimerization. <i>Molecular Cell</i> , 2000, 6, 743-750.	9.7	1,024
5	Receptor Specificity of the Fibroblast Growth Factor Family. <i>Journal of Biological Chemistry</i> , 2006, 281, 15694-15700.	3.4	986
6	Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. <i>Nature</i> , 1995, 373, 536-539.	27.8	932
7	The parathyroid is a target organ for FGF23 in rats. <i>Journal of Clinical Investigation</i> , 2007, 117, 4003-8.	8.2	802
8	Cloning of PI3 kinase-associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases. <i>Cell</i> , 1991, 65, 83-90.	28.9	674
9	Tissue-specific Expression of β 2Klotho and Fibroblast Growth Factor (FGF) Receptor Isoforms Determines Metabolic Activity of FGF19 and FGF21. <i>Journal of Biological Chemistry</i> , 2007, 282, 26687-26695.	3.4	654
10	Structural basis for fibroblast growth factor receptor activation. <i>Cytokine and Growth Factor Reviews</i> , 2005, 16, 107-137.	7.2	625
11	The function of GRB2 in linking the insulin receptor to Ras signaling pathways. <i>Science</i> , 1993, 260, 1953-1955.	12.6	608
12	FGF21 induces PGC-1 α and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 10853-10858.	7.1	605
13	Research Resource: Comprehensive Expression Atlas of the Fibroblast Growth Factor System in Adult Mouse. <i>Molecular Endocrinology</i> , 2010, 24, 2050-2064.	3.7	579
14	Structural Basis for FGF Receptor Dimerization and Activation. <i>Cell</i> , 1999, 98, 641-650.	28.9	575
15	β 2Klotho is required for metabolic activity of fibroblast growth factor 21. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 7432-7437.	7.1	516
16	Circulating FGF21 Is Liver Derived and Enhances Glucose Uptake During Refeeding and Overfeeding. <i>Diabetes</i> , 2014, 63, 4057-4063.	0.6	467
17	Molecular Insights into the Klotho-Dependent, Endocrine Mode of Action of Fibroblast Growth Factor 19 Subfamily Members. <i>Molecular and Cellular Biology</i> , 2007, 27, 3417-3428.	2.3	457
18	Exploring mechanisms of FGF signalling through the lens of structural biology. <i>Nature Reviews Molecular Cell Biology</i> , 2013, 14, 166-180.	37.0	449

#	ARTICLE	IF	CITATIONS
19	Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. <i>EMBO Journal</i> , 1998, 17, 5896-5904.	7.8	443
20	Point mutation in FGF receptor eliminates phosphatidylinositol hydrolysis without affecting mitogenesis. <i>Nature</i> , 1992, 358, 681-684.	27.8	438
21	A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. <i>Journal of Clinical Investigation</i> , 2007, 117, 2684-2691.	8.2	390
22	Structure of the FGF Receptor Tyrosine Kinase Domain Reveals a Novel Autoinhibitory Mechanism. <i>Cell</i> , 1996, 86, 577-587.	28.9	378
23	SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. <i>Cancer Research</i> , 2000, 60, 4152-60.	0.9	378
24	Crystal Structures of Two FGF-FGFR Complexes Reveal the Determinants of Ligand-Receptor Specificity. <i>Cell</i> , 2000, 101, 413-424.	28.9	370
25	FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 297, F282-F291.	2.7	361
26	Identification of Six Novel Autophosphorylation Sites on Fibroblast Growth Factor Receptor 1 and Elucidation of Their Importance in Receptor Activation and Signal Transduction. <i>Molecular and Cellular Biology</i> , 1996, 16, 977-989.	2.3	360
27	Inhibition of Growth Hormone Signaling by the Fasting-Induced Hormone FGF21. <i>Cell Metabolism</i> , 2008, 8, 77-83.	16.2	353
28	Î±-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling. <i>Nature</i> , 2018, 553, 461-466.	27.8	348
29	Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice. <i>Journal of Clinical Investigation</i> , 2008, 118, 2822-2831.	8.2	348
30	Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism. <i>Journal of Clinical Investigation</i> , 2007, 117, 457-463.	8.2	338
31	Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor Î³. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 3143-3148.	7.1	331
32	Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 407-412.	7.1	327
33	Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. <i>Oncogene</i> , 2007, 26, 7158-7162.	5.9	284
34	Autoregulatory Mechanisms in Protein-tyrosine Kinases. <i>Journal of Biological Chemistry</i> , 1998, 273, 11987-11990.	3.4	262
35	Tyr Phosphorylation of PDP1 Toggles Recruitment between ACAT1 and SIRT3 to Regulate the Pyruvate Dehydrogenase Complex. <i>Molecular Cell</i> , 2014, 53, 534-548.	9.7	247
36	Impaired FGF signaling contributes to cleft lip and palate. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 4512-4517.	7.1	246

#	ARTICLE	IF	CITATIONS
37	<i>In vivo</i> genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23)-mediated regulation of systemic phosphate homeostasis. <i>FASEB Journal</i> , 2009, 23, 433-441.	0.5	235
38	Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 Are Identified in Individuals with Congenital Hypogonadotropic Hypogonadism. <i>American Journal of Human Genetics</i> , 2013, 92, 725-743.	6.2	227
39	Mutations in fibroblast growth factor receptor 1 cause both Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 6281-6286.	7.1	225
40	Fibroblast Growth Factor (FGF) Homologous Factors Share Structural but Not Functional Homology with FGFs. <i>Journal of Biological Chemistry</i> , 2003, 278, 34226-34236.	3.4	221
41	A Molecular Brake in the Kinase Hinge Region Regulates the Activity of Receptor Tyrosine Kinases. <i>Molecular Cell</i> , 2007, 27, 717-730.	9.7	221
42	Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer. <i>Nature</i> , 2014, 513, 436-439.	27.8	201
43	Molecular Mechanisms of Fibroblast Growth Factor Signaling in Physiology and Pathology. <i>Cold Spring Harbor Perspectives in Biology</i> , 2013, 5, a015958-a015958.	5.5	195
44	Analysis of the Biochemical Mechanisms for the Endocrine Actions of Fibroblast Growth Factor-23. <i>Endocrinology</i> , 2005, 146, 4647-4656.	2.8	192
45	Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 7182-7187.	7.1	187
46	Differential Interactions of FGFs with Heparan Sulfate Control Gradient Formation and Branching Morphogenesis. <i>Science Signaling</i> , 2009, 2, ra55.	3.6	178
47	Mutations in fibroblast growth factor receptor 1 cause Kallmann syndrome with a wide spectrum of reproductive phenotypes. <i>Molecular and Cellular Endocrinology</i> , 2006, 254-255, 60-69.	3.2	176
48	FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1/2-SGK1 signaling pathway. <i>Bone</i> , 2012, 51, 621-628.	2.9	176
49	Structural basis by which alternative splicing modulates the organizer activity of FGF8 in the brain. <i>Genes and Development</i> , 2006, 20, 185-198.	5.9	171
50	Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 935-940.	7.1	168
51	Kinetic Model for FGF, FGFR, and Proteoglycan Signal Transduction Complex Assembly. <i>Biochemistry</i> , 2004, 43, 4724-4730.	2.5	163
52	Structural basis by which alternative splicing confers specificity in fibroblast growth factor receptors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 2266-2271.	7.1	161
53	FGF23 promotes renal calcium reabsorption through the TRPV5 channel. <i>EMBO Journal</i> , 2014, 33, n/a-n/a.	7.8	159
54	Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E4869-77.	7.1	154

#	ARTICLE	IF	CITATIONS
55	Parathyroid-Specific Deletion of Klotho Unravels a Novel Calcineurin-Dependent FGF23 Signaling Pathway That Regulates PTH Secretion. <i>PLoS Genetics</i> , 2013, 9, e1003975.	3.5	139
56	Genetic Overlap in Kallmann Syndrome, Combined Pituitary Hormone Deficiency, and Septo-Optic Dysplasia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E694-E699.	3.6	136
57	A protein canyon in the FGF-FGF receptor dimer selects from an à la carte menu of heparan sulfate motifs. <i>Current Opinion in Structural Biology</i> , 2005, 15, 506-516.	5.7	132
58	Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities. <i>Human Molecular Genetics</i> , 2004, 13, 2313-2324.	2.9	131
59	SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: identification of Tyr992 as the high-affinity binding site for SH2 domains of phospholipase C gamma. <i>EMBO Journal</i> , 1992, 11, 559-67.	7.8	127
60	Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and mice. <i>Journal of Clinical Investigation</i> , 2011, 121, 3220-3232.	8.2	125
61	The demonstration of Klotho deficiency in human chronic kidney disease with a novel synthetic antibody. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 223-233.	0.7	124
62	Arterial Klotho Expression and FGF23 Effects on Vascular Calcification and Function. <i>PLoS ONE</i> , 2013, 8, e60658.	2.5	123
63	Crystal Structure of a Fibroblast Growth Factor Homologous Factor (FHF) Defines a Conserved Surface on FHFs for Binding and Modulation of Voltage-gated Sodium Channels. <i>Journal of Biological Chemistry</i> , 2009, 284, 17883-17896.	3.4	121
64	Proline to arginine mutations in FGF receptors 1 and 3 result in Pfeiffer and Muenke craniosynostosis syndromes through enhancement of FGF binding affinity. <i>Human Molecular Genetics</i> , 2003, 13, 69-78.	2.9	118
65	Fibroblast growth factor 1 ameliorates diabetic nephropathy by an anti-inflammatory mechanism. <i>Kidney International</i> , 2018, 93, 95-109.	5.2	117
66	The N550K/H Mutations in FGFR2 Confer Differential Resistance to PD173074, Dovitinib, and Ponatinib ATP-Competitive Inhibitors. <i>Neoplasia</i> , 2013, 15, 975-IN30.	5.3	116
67	Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in Melanoma. <i>Molecular Cancer Research</i> , 2009, 7, 41-54.	3.4	112
68	FGF-23-Klotho signaling stimulates proliferation and prevents vitamin D-induced apoptosis. <i>Journal of Cell Biology</i> , 2008, 182, 459-465.	5.2	110
69	Internalization of fibroblast growth factor receptor is inhibited by a point mutation at tyrosine 766. <i>Journal of Biological Chemistry</i> , 1994, 269, 17056-61.	3.4	95
70	Reduced Activation of RAF-1 and MAP Kinase by a Fibroblast Growth Factor Receptor Mutant Deficient in Stimulation of Phosphatidylinositol Hydrolysis. <i>Journal of Biological Chemistry</i> , 1995, 270, 5065-5072.	3.4	94
71	Regulation of serum 1,25(OH) ₂ Vitamin D ₃ levels by fibroblast growth factor 23 is mediated by FGF receptors 3 and 4. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 301, F371-F377.	2.7	93
72	Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia. <i>FASEB Journal</i> , 2018, 32, 3752-3764.	0.5	85

#	ARTICLE	IF	CITATIONS
73	FGF21 mediates alcohol-induced adipose tissue lipolysis by activation of systemic release of catecholamine in mice. <i>Journal of Lipid Research</i> , 2015, 56, 1481-1491.	4.2	83
74	Impaired Fibroblast Growth Factor Receptor 1 Signaling as a Cause of Normosmic Idiopathic Hypogonadotropic Hypogonadism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4380-4390.	3.6	82
75	Fibroblast growth factor signalling in osteoarthritis and cartilage repair. <i>Nature Reviews Rheumatology</i> , 2020, 16, 547-564.	8.0	81
76	Conversion of a Paracrine Fibroblast Growth Factor into an Endocrine Fibroblast Growth Factor. <i>Journal of Biological Chemistry</i> , 2012, 287, 29134-29146.	3.4	79
77	A Single Amino Acid Substitution in the Activation Loop Defines the Decoy Characteristic of VEGFR-1/FLT-1. <i>Journal of Biological Chemistry</i> , 2006, 281, 867-875.	3.4	78
78	<i>KLB</i> , encoding β -Klotho, is mutated in patients with congenital hypogonadotropic hypogonadism. <i>EMBO Molecular Medicine</i> , 2017, 9, 1379-1397.	6.9	77
79	Klotho Coreceptors Inhibit Signaling by Paracrine Fibroblast Growth Factor 8 Subfamily Ligands. <i>Molecular and Cellular Biology</i> , 2012, 32, 1944-1954.	2.3	74
80	Grb2, a Double-Edged Sword of Receptor Tyrosine Kinase Signaling. <i>Science Signaling</i> , 2012, 5, pe49.	3.6	71
81	Uncoupling the Mitogenic and Metabolic Functions of FGF1 by Tuning FGF1-FGF Receptor Dimer Stability. <i>Cell Reports</i> , 2017, 20, 1717-1728.	6.4	71
82	Nonsense Mutations in <i>FGF8</i> Gene Causing Different Degrees of Human Gonadotropin-Releasing Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 3491-3496.	3.6	70
83	The Structural Biology of the FGF19 Subfamily. <i>Advances in Experimental Medicine and Biology</i> , 2012, 728, 1-24.	1.6	70
84	Compositional Analysis of Heparin/Heparan Sulfate Interacting with Fibroblast Growth Factor-Fibroblast Growth Factor Receptor Complexes. <i>Biochemistry</i> , 2009, 48, 8379-8386.	2.5	67
85	FGF6 and FGF9 regulate UCP1 expression independent of brown adipogenesis. <i>Nature Communications</i> , 2020, 11, 1421.	12.8	67
86	The Alternatively Spliced Acid Box Region Plays a Key Role in FGF Receptor Autoinhibition. <i>Structure</i> , 2012, 20, 77-88.	3.3	66
87	Point mutation in the fibroblast growth factor receptor eliminates phosphatidylinositol hydrolysis without affecting neuronal differentiation of PC12 cells. <i>Journal of Biological Chemistry</i> , 1994, 269, 14419-23.	3.4	66
88	Identification of Receptor and Heparin Binding Sites in Fibroblast Growth Factor 4 by Structure-Based Mutagenesis. <i>Molecular and Cellular Biology</i> , 2001, 21, 5946-5957.	2.3	62
89	Crystal Structure of Fibroblast Growth Factor 9 Reveals Regions Implicated in Dimerization and Autoinhibition. <i>Journal of Biological Chemistry</i> , 2001, 276, 4322-4329.	3.4	62
90	A crystallographic snapshot of tyrosine <i>trans</i> -phosphorylation in action. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 19660-19665.	7.1	61

#	ARTICLE	IF	CITATIONS
91	Analysis of Mutations in Fibroblast Growth Factor (FGF) and a Pathogenic Mutation in FGF Receptor (FGFR) Provides Direct Evidence for the Symmetric Two-End Model for FGFR Dimerization. <i>Molecular and Cellular Biology</i> , 2005, 25, 671-684.	2.3	58
92	Fibroblast growth factor 21 deficiency exacerbates chronic alcohol-induced hepatic steatosis and injury. <i>Scientific Reports</i> , 2016, 6, 31026.	3.3	58
93	Aggregation-induced activation of the epidermal growth factor receptor protein tyrosine kinase. <i>Biochemistry</i> , 1993, 32, 8742-8748.	2.5	55
94	Congenital hypogonadotropic hypogonadism with split hand/foot malformation: a clinical entity with a high frequency of FGFR1 mutations. <i>Genetics in Medicine</i> , 2015, 17, 651-659.	2.4	55
95	Understanding the molecular basis of Apert syndrome. <i>Plastic and Reconstructive Surgery</i> , 2005, 115, 264-70.	1.4	53
96	A threshold model for receptor tyrosine kinase signaling specificity and cell fate determination. <i>F1000Research</i> , 2018, 7, 872.	1.6	52
97	Structural Basis for Activation of Fibroblast Growth Factor Signaling by Sucrose Octasulfate. <i>Molecular and Cellular Biology</i> , 2002, 22, 7184-7192.	2.3	51
98	Identification of Phosphopeptides by MALDI Q-TOF MS in Positive and Negative Ion Modes after Methyl Esterification. <i>Molecular and Cellular Proteomics</i> , 2005, 4, 809-818.	3.8	48
99	Two FGF Receptor Kinase Molecules Act in Concert to Recruit and Transphosphorylate Phospholipase C β . <i>Molecular Cell</i> , 2016, 61, 98-110.	9.7	48
100	Homodimerization Controls the Fibroblast Growth Factor 9 Subfamily's Receptor Binding and Heparan Sulfate-Dependent Diffusion in the Extracellular Matrix. <i>Molecular and Cellular Biology</i> , 2009, 29, 4663-4678.	2.3	44
101	Cracking the Molecular Origin of Intrinsic Tyrosine Kinase Activity through Analysis of Pathogenic Gain-of-Function Mutations. <i>Cell Reports</i> , 2013, 4, 376-384.	6.4	44
102	DFG-out Mode of Inhibition by an Irreversible Type-1 Inhibitor Capable of Overcoming Gate-Keeper Mutations in FGF Receptors. <i>ACS Chemical Biology</i> , 2015, 10, 299-309.	3.4	44
103	Activating Adenosine Monophosphate-Activated Protein Kinase Mediates Fibroblast Growth Factor 1 Protection From Nonalcoholic Fatty Liver Disease in Mice. <i>Hepatology</i> , 2021, 73, 2206-2222.	7.3	43
104	β -Klotho deficiency protects against obesity through a crosstalk between liver, microbiota, and brown adipose tissue. <i>JCI Insight</i> , 2017, 2, .	5.0	41
105	Structural Mimicry of A-Loop Tyrosine Phosphorylation by a Pathogenic FGF Receptor 3 Mutation. <i>Structure</i> , 2013, 21, 1889-1896.	3.3	39
106	Elucidation of a four-site allosteric network in fibroblast growth factor receptor tyrosine kinases. <i>ELife</i> , 2017, 6, .	6.0	38
107	Plasticity in Interactions of Fibroblast Growth Factor 1 (FGF1) N Terminus with FGF Receptors Underlies Promiscuity of FGF1. <i>Journal of Biological Chemistry</i> , 2012, 287, 3067-3078.	3.4	37
108	Structural Biology of the FGF7 Subfamily. <i>Frontiers in Genetics</i> , 2019, 10, 102.	2.3	36

#	ARTICLE	IF	CITATIONS
109	Paracrine FGFs target skeletal muscle to exert potent anti-hyperglycemic effects. <i>Nature Communications</i> , 2021, 12, 7256.	12.8	32
110	Somatic <i>FGF9</i> mutations in colorectal and endometrial carcinomas associated with membranous β -catenin. <i>Human Mutation</i> , 2008, 29, 390-397.	2.5	31
111	Molecular basis for receptor tyrosine kinase A-loop tyrosine transphosphorylation. <i>Nature Chemical Biology</i> , 2020, 16, 267-277.	8.0	31
112	Influence of Heparin Mimetics on Assembly of the FGF-FGFR4 Signaling Complex. <i>Journal of Biological Chemistry</i> , 2010, 285, 26628-26640.	3.4	30
113	Different Tyrosine Autophosphorylation Requirements in Fibroblast Growth Factor Receptor-1 Mediate Urokinase-Type Plasminogen Activator Induction and Mitogenesis. <i>Molecular Biology of the Cell</i> , 1999, 10, 23-33.	2.1	27
114	Graded Levels of FGF Protein Span the Midbrain and Can Instruct Graded Induction and Repression of Neural Mapping Labels. <i>Neuron</i> , 2009, 62, 773-780.	8.1	27
115	Regulation of Receptor Binding Specificity of FGF9 by an Autoinhibitory Homodimerization. <i>Structure</i> , 2017, 25, 1325-1336.e3.	3.3	25
116	A novel fibroblast growth factor-1 ligand with reduced heparin binding protects the heart against ischemia-reperfusion injury in the presence of heparin co-administration. <i>Cardiovascular Research</i> , 2017, 113, 1585-1602.	3.8	23
117	Therapeutic Effects of FGF23 c-tail Fc in a Murine Preclinical Model of X-Linked Hypophosphatemia Via the Selective Modulation of Phosphate Reabsorption. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 2062-2073.	2.8	22
118	Induction of Urokinase-type Plasminogen Activator by Fibroblast Growth Factor (FGF)-2 Is Dependent on Expression of FGF Receptors and Does Not Require Activation of Phospholipase C β 1. <i>Journal of Biological Chemistry</i> , 1996, 271, 31154-31159.	3.4	21
119	Urothelial tumor initiation requires deregulation of multiple signaling pathways: implications in target-based therapies. <i>Carcinogenesis</i> , 2012, 33, 770-780.	2.8	20
120	C-FGF23 peptide alleviates hypoferrremia during acute inflammation. <i>Haematologica</i> , 2021, 106, 391-403.	3.5	19
121	Differential pre- and postsynaptic modulation of chemical transmission in the squid giant synapse by tyrosine phosphorylation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 1990-1994.	7.1	18
122	Paracrine-endocrine FGF chimeras as potent therapeutics for metabolic diseases. <i>EBioMedicine</i> , 2019, 48, 462-477.	6.1	17
123	A Conserved Allosteric Pathway in Tyrosine Kinase Regulation. <i>Structure</i> , 2019, 27, 1308-1315.e3.	3.3	16
124	A G protein-coupled, IP3/protein kinase C pathway controlling the synthesis of phosphaturic hormone FGF23. <i>JCI Insight</i> , 2019, 4, .	5.0	16
125	Curtailing FGF19's mitogenicity by suppressing its receptor dimerization ability. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 29025-29034.	7.1	15
126	Role of SH2-containing Proteins in Cellular Signaling by Receptor Tyrosine Kinases. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 1992, 57, 67-74.	1.1	15

#	ARTICLE	IF	CITATIONS
127	Genetic testing facilitates prepubertal diagnosis of congenital hypogonadotropic hypogonadism. <i>Clinical Genetics</i> , 2017, 92, 213-216.	2.0	14
128	Rhenium N-heterocyclic carbene complexes block growth of aggressive cancers by inhibiting FGFR- and SRC-mediated signalling. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 276.	8.6	14
129	Structure-based mutational analyses in FGF7 identify new residues involved in specific interaction with FGFR2IIIb. <i>FEBS Letters</i> , 2003, 552, 150-154.	2.8	13
130	Fibroblast Growth Factor Binding Protein 3 (FGFBP3) impacts carbohydrate and lipid metabolism. <i>Scientific Reports</i> , 2018, 8, 15973.	3.3	12
131	FGF23-Induced Hypophosphatemia Persists in HypMice Deficient in the WNT Coreceptor Lrp6. <i>Contributions To Nephrology</i> , 2013, 180, 124-137.	1.1	11
132	Fibulin-1 Binds to Fibroblast Growth Factor 8 with High Affinity. <i>Journal of Biological Chemistry</i> , 2016, 291, 18730-18739.	3.4	10
133	InÂvitro reconstitution reveals cooperative mechanisms of adapter protein-mediated activation of phospholipase C-Î³1 in T cells. <i>Journal of Biological Chemistry</i> , 2022, 298, 101680.	3.4	5
134	Synthesis of sulfosucrose derivatives for evaluation as regulators of fibroblast growth factor activity. <i>Tetrahedron Letters</i> , 2002, 43, 8047-8049.	1.4	4
135	Hedgehogs like it sweet, too. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 17069-17070.	7.1	2
136	NMR Experiments on Wild-Type and Mutant Fibroblast Growth Factor Receptor Kinases Reveal Conformational Dynamics Associated with Enzyme Activation. <i>Biophysical Journal</i> , 2016, 110, 220a.	0.5	0
137	Two FGF Receptor Kinase Molecules Act in Concert to Recruit and Transphosphorylate Phospholipase CÎ³. <i>Molecular Cell</i> , 2016, 61, 324.	9.7	0
138	FGF-FGFR Signaling in Cancer. , 2017, , 577-590.		0
139	Characterization of Disease Causing Mutations Associated with FGF Receptor Tyrosine Kinases using NMR Spectroscopy. <i>Biophysical Journal</i> , 2017, 112, 64a.	0.5	0
140	Structural basis of FGF23 hormone signaling. , 2021, , 299-318.		0
141	FGF-FGFR Signaling in Cancer. , 2014, , 1-14.		0